00847.Abstract REVIEW ARTICLE BEYOND INSULIN REPLACEMENT: ADDRESSING THE ADDITIONAL NEEDS OF THE DIABETES PATIENT G.Of Diabetes and Endocrinology, Scripps Clinic Torrey Pines, San Diego, CA, USAGeorge Dailey, Department of Diabetes and Endocrinology, Scripps Clinic Torrey Pines, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA.1Department of Diabetes and Endocrinology, Scripps Clinic Torrey Pines, San Diego, CA, USA George Dailey, Department of Diabetes and Endocrinology, Scripps Clinic Torrey Pines, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA.INTEREST: G.Has served as an investigator, speaker and occasional consultant for sanofi-aventis as well as Eli Lilly andpany, Novo Nordisk, Amylin and Merck (USA).Of type 2 diabetes mellitus (T2DM) typically focuses on correcting dysglycaemia to reduce risk for microvascular and macrovascularplications, possibly by reducing glucose-mediated oxidative stress.Other cardiometabolic risk factors, including abdominal obesity and dyslipidaemia are often overlooked in the quest for perfect glucose control.Currently used antidiabetic agents, including insulin, metformin, sulphonylureas and thiazolidinediones, have limited efficacy on these risk factors.Number of new therapeutic agents are undergoing clinical development, including glucagon-like peptide 1 mimetics (exenatide and liraglutide) and dipeptidyl peptidase 4 inhibitors (sitagliptin and vildagliptin), which target the incretin system, and the cannabinoid-1 receptor antagonists (rimonabant), which target the endocannabinoid system, may hold some promise for meeting these unmet needs.This review, the clinical properties of these agents and potential treatment pathways to best use these agents are discussed for improving the management of T2DM and cardiovascular risk.Read more Abbott receives fda approval for simcor® (niaspan® / simvastatin), a novel combination medicine for comprehensive cholesterol management
Get more Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (ras) in veins: a randomized double-blind crossover trial in healthy subjects
